EUVIMEDEUVIMED entdecken
Crossref

Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer

Xue Wei, Ming Yang, Haoyang Zou, Songjie Shen, Yuechong Li, Li Chen, Yahui Liu, Di Li, Jianxun Ding

Journal of Controlled Release · 2025

DOI: 10.1016/j.jconrel.2025.02.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Xue Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China; Key Labora…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Benzimidazoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jilin University, Jilin Provincial Scientific and Technological Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) selectively arrest malignant cells in the G1 phase of cell cycle by inhibiting CDK4/6-mediated phosphorylation of retinoblastoma protein. However, CDK4/6i therapy is often ineffective against triple-negative breast cancer (TNBC) due to the high lysosomal content in TNBC cells, which sequesters the drugs and prevents them from reaching their nuclear target. To address this challenge, three pH- and glutathione-responsive poly(amino acid) nanogels composed of methoxy poly(ethylene glycol) of various lengths and poly(L-glutamic acid-co-L-cystine) (mPEG-P(Glu10-co-Cys25)) were developed to efficiently deliver the CDK4/6i abemaciclib (ABE) to TNBC cells. These nanogels bypassed lysosomal sequestration, thereby enhancing the efficacy of molecularly targeted immunotherapy. Among the nanogels, the formulation with mPEG2000 (NG2000) exhibited the highest efficiency in delivering ABE, resulting in increased cell apoptosis, activation of an anti-cancer immune response, reduction of immunosuppression, and improved therapeutic outcomes against TNBC. Furthermore, NG2000/ABE enhanced immune checkpoint therapy for TNBC, achieving a tumor inhibition rate of 89.66%. These findings demonstrate the potential of poly(amino acid) nanoformulations for delivering CDK4/6 inhibitors as molecularly targeted immunotherapy for TNBC in clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6BenzimidazolesAminopyridinesProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleCell Line, TumorAnimalsImmunotherapyPolyethylene GlycolsMice, NudeMiceNanoparticlesMice, Inbred BALB CGlutathioneDrug Liberation

Stichwörter der Autor:innen

Immunogenic cell deathMolecularly targeted immunotherapyPoly(amino acid) nanogelReduction of lysosomal sequestrationTriple-negative breast cancer

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6abemaciclibBenzimidazolesAminopyridinesCDK4 protein, humanProtein Kinase InhibitorsPolyethylene GlycolsAntineoplastic AgentsCDK6 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry…
  • Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China. Electronic address: yangming@jlu.edu.cn.
  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
  • Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Beijing 100730, PR China.
  • Department of Chemistry, Northeast Normal University, 5268 Renmin Street, Changchun 130024, PR China.
  • Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, 1 Xinmin Street, Changchun 130061, PR China. Electronic address: yahui@jlu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Jilin University
  • Jilin Provincial Scientific and Technological Development Program

Zitieren

APA

Wei, X., Yang, M., Zou, H., Shen, S., Li, Y., Chen, L., Liu, Y., Li, D., & Ding, J. (2025). Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.02.020

Vancouver

Wei X, Yang M, Zou H, Shen S, Li Y, Chen L, et al. Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.02.020

BibTeX
@article{Wei2025,
  author = {Wei, Xue and Yang, Ming and Zou, Haoyang and Shen, Songjie and Li, Yuechong and Chen, Li and Liu, Yahui and Li, Di and Ding, Jianxun},
  title = {Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer},
  journal = {Journal of Controlled Release},
  year = {2025},
  doi = {10.1016/j.jconrel.2025.02.020}
}
Kostenlos starten →